It's simply the fact that patients are choosing to continue Arikace treatment after the trial finishes rather than go back to Tobi or any other inhaleable treatment. Lewis shared this with us on the CC, and just like his insider purchases when the risk was still out there on the preclinical data, this one fact alone speaks volumes about the near-term success for Arikace and its parent company Insmed. I am fairly sure that the guys buying these huge blocks of shares recruited Seeking Alpha to cover for their buy-in by writing the article about the near-term catalyst. These things just don't happen coincidentally. Another great day shaping up!!! GO INSM.